Literatur
- 1
Akin C, Fumo G, Yavuz A S, Lipsky P E, Neckers L, Metcalfe D D.
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response
to imatinib.
Blood.
2004;
103
3222-3225
- 2
Bauer C, Ruëff F, Przybilla B.
Notfälle in der Allergologie.
Hautarzt.
2004;
55
525-532
- 3
Blunk J A, Schmelz M, Zeck S, Skov P, Likar R, Koppert W.
Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid
receptors: an in vivo microdialysis study in human skin.
Anesth Analg.
2004;
98
364-370
- 4
Bucher B, Simic P, Furrer J, Wüthrich B.
Mastozytose: eine wichtige Differentialdiagnose bei anaphylaktischer Reaktion auf
Hymenopterenstiche.
Schweiz Rundsch Med Prax.
2000;
89
411-418
- 5
Brockow K, Scott L M, Worobec A S, Kirshenbaum A, Akin C, Huber M M, Metcalfe D D.
Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation
with clinical patterns of disease.
Arch Dermatol.
2002;
138
785-790
- 6
Brockow K, Akin C, Huber M, Metcalfe D D.
Assessment of the extent of cutaneous involvement in children and adults with mastocytosis:
relationship to symptomatology, tryptase levels, and bone marrow pathology.
J Am Acad Dermatol.
2003;
48
508-516
- 7
Czarnetzki B M, Kolde G, Schoemann A, Urbanitz S, Urbanitz D.
Bone marrow findings in adult patients with urticaria pigmentosa.
J Am Acad Dermatol.
1988;
18
45-51
- 8
Delling G, Ritzel H, Werner M.
Histologische Charakteristika und Häufigkeit der sekundären Osteoporose bei systemischer
Mastozytose. Eine retrospektive Analyse an 158 Fällen.
Pathologe.
2001;
22
132-140
- 9
Dugas-Breit S, Schopf P, Dugas M, Schiffl H, Rueff F, Przybilla B.
Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and
associated with severity of pruritus.
J Dtsch Dermatol Ges.
2005;
3
343-347
- 10
Fearfield L A, Francis N, Henry K, Costello C, Bunker C B.
Bone marrow involvement in cutaneous mastocytosis.
Br J Dermatol.
2001;
144
561-566
- 11
Florian S, Krauth M T, Simonitsch-Klupp I, Sperr W R, Fritsche-Polanz R, Sonneck K,
Fodinger M, Agis H, Bohm A, Wimazal F, Horny H P, Valent P.
Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions,
and recurrent severe anaphylactoid episodes.
Int Arch Allergy Immunol.
2005;
136
273-280
- 12
Fricker M, Helbling A, Schwartz L, Müller U.
Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results
of venom immunotherapy in ten patients.
J Allergy Clin Immunol.
1997;
100
11-15
- 13
Golkar L, Bernhard J D.
Mastocytosis.
Lancet.
1997;
349
1379-1385
- 14
Hartmann K, Metcalfe D D.
Pediatric mastocytosis.
Hematol Oncol Clin North Am.
2000;
14
625-640
- 15
Hidvegi B, Nagy E, Szabo T, Temesvari E, Marschalko M, Karpati S, Horvath A, Gergely P.
Correlation between T-cell and mast cell activity in patients with chronic urticaria.
Int Arch Allergy Immunol.
2003;
132
177-182
- 16
Horan R F, Austen K F.
Systemic mastocytosis: retrospective review of a decade’s clinical experience at the
Brigham and Women’s Hospital.
J Invest Dermatol.
1991;
96
5S-14S
- 17
Kettelhut B V, Metcalfe D D.
Pediatric mastocytosis.
Ann Allergy.
1994;
73
197-202
- 18
Kiszewski A E, Duran-Mckinster C, Orozco-Covarrubias L, Gutierrez-Castrellon P, Ruiz-Maldonado R.
Cutaneous mastocytosis in children: a clinical analysis of 71 cases.
J Eur Acad Dermatol Venereol.
2004;
18
285-290
- 19
Kors J W, Van Doormaal J J, Breukelman H, Van Voorst Vader P C, De Monchy J G.
Long-term follow-up of indolent mastocytosis in adults.
J Intern Med.
1996;
239
157-164
- 20
Kränke B, Sturm G, Aberer W.
Negative venom skin test results and mastocytosis.
J Allergy Clin Immunol.
2004;
113
180-181
- 21
Lawrence J B, Friedman B S, Travis W D, Chinchilli V M, Metcalfe D D, Gralnick H R.
Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory
and morphologic features and their relation to prognosis.
Am J Med.
1991;
91
612-624
- 22
Ludolph-Hauser D, Ruëff F, Fries C, Schöpf P, Przybilla B.
Constitutionally raised serum concentrations of mast-cell tryptase and severe anaphylactic
reactions to Hymenoptera stings.
Lancet.
2001;
357
361-362
- 23
Ludolph-Hauser D, Schöpf P, Ruëff F, Przybilla B.
Okkulte kutane Mastozytose.
Hautarzt.
2001;
52
390-393
- 24
Marone G, Stellato C, Mastronardi P, Mazzarella B.
Mechanisms of activation of human mast cells and basophils by general anesthetic drugs.
Ann Fr Anesth Reanim.
1993;
12
116-125
- 25
Middelkamp Hup M A, Heide R, Tank B, Mulder P G, Oranje A P.
Comparison of mastocytosis with onset in children and adults.
J Eur Acad Dermatol Venereol.
2002;
16
115-120
- 26
Möller R, Paul E.
Acetylsalicylsäure als Augmentationsfaktor einer Nahrungsmittel-Allergie.
Hautarzt.
1996;
47
281-283
- 27
Müller U, Helbling A, Hunziker T, Wuthrich B, Pecoud A, Gilardi S, Beretta E, Fasel J,
Messerli W, Maurer P.
Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa.
Allergy.
1990;
45
597-603
- 28
Oude Elberink J NG, de Monchy J GR, Kors J W, van Doormaal J J, Dubois A EJ.
Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two
patients with mastocytosis.
J Allergy Clin Immunol.
1997;
99
153-154
- 29
Pardanani A, Kimlinger T K, Reeder T L, Li C Y, Tefferi A.
Differential expression of CD2 on neoplastic mast cells in patients with systemic
mast cell disease with and without an associated clonal haematological disorder.
Br J Haematol.
2003;
120
691-694
- 30
Pardanani A, Ketterling R P, Brockman S R, Flynn H C, Paternoster S F, Shearer B M,
Reeder T L, Li C Y, Cross N C, Cools J, Gilliland D G, Dewald G W, Tefferi A.
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis
associated with eosinophilia and predicts response to imatinib mesylate therapy.
Blood.
2003;
102
3093-3096
- 31
Pardanani A.
Systemic mastocytosis: bone marrow pathology, classification, and current therapies.
Acta Haematol.
2005;
114
41-51
- 32
Przybilla B, Müller U, Jarisch R, Ruëff F.
Erhöhte basale Serumtryptasekonzentration oder Mastozytose als Risikofaktor der Hymenopterengiftallergie.
Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie.
Allergo J.
2004;
3
440-442
- 33
Raisz L.
Pathogenesis of osteoporosis: concepts, conflicts, and prospects.
J Clin Invest.
2005;
115
3318-2225
- 34
Rodermund O E, Klingmuller G, Rohner H G.
Interne Befunde bei Mastozytose.
Hautarzt.
1980;
31
175-178
- 35
Rosbotham J L, Malik N M, Syrris P, Jeffery S, Bedlow A, Gharraie S, Murday V A, Holden C A,
Carter N D.
Lack of c-kit mutation in familial urticaria pigmentosa.
Br J Dermatol.
1999;
140
849-852
- 36
Ruëff F, Wenderoth A, Przybilla B.
Patients still reacting to a sting challenge while receiving Hymenoptera venom immunotherapy
are protected by increased venom doses.
J Allergy Clin Immunol.
2001;
108
1027-1032
- 37
Ruëff F, Dugas-Breit S, Bauer C, Schöpf P, Albert K, Marx R, Przybilla B.
Diagnose und Therapie der Insektengiftallergie bei Mastozytose.
Allergo J.
2005;
14
514-515
- 38
Ruëff F, Bauer C, Albert K, Przybilla B.
Mastocytosis is a stronger risk factor for treatment failure of Hymenoptera venom
immunotherapy than elevated baseline serum tryptase.
Allergy Clin Immunol Int - J WAO Org.
2005;
(Suppl 1)
17
69
- 39
Sagher F, Even-Paz Z.
Mastocytosis and the mast cell: Chicago: Year Book Medical Publishers, 1967 (zitiert
nach Golkar L, Bernhard JD. Mastocytosis).
Lancet.
1997;
349
1379-1385
- 40
Schwartz L B, Metcalfe D D, Miller J S, Earl H, Sullivan T.
Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and
mastocytosis.
N Engl J Med.
1987;
316
1622-1626
- 41
Schwartz L B, Bradford T B, Rouse C, Irani A -M, Rasp G, van der Zwan J K, van der
Linden P -WG.
Development of a new, more sensitive immunoassy for human tryptase: use in systemic
anaphylaxis.
J Clin Immunol.
1994;
14
190-204
- 42
Schwartz L B, Sakai K, Bradford T R, Ren S, Zweimann B, Worobec A S.
The alpha form of human tryptase is the predominant type present in blood at baseline
in normal subjects and is elevated in those with systemic mastocytosis.
J Clin Invest.
1995;
96
2702-2710
- 43
Siegert S I, Diebold J, Ludolph-Hauser D, Lohrs U.
Are gastrointestinal mucosal mast cells increased in patients with systemic mastocytosis?.
Am J Clin Pathol.
2004;
122
560-565
- 44
Sotlar K, Horny H P, Simonitsch I, Krokowski M, Aichberger K J, Mayerhofer M, Printz D,
Fritsch G, Valent P.
CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical
marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone
marrow biopsy specimens.
Am J Surg Pathol.
2004;
28
1319-1325
- 45
Sperr W R, Stehberger B, Wimazal F, Baghestanian M, Schwartz L B, Kundi M, Semper H,
Jordan J H, Chott A, Drach J, Jager U, Geissler K, Greschniok A, Horny H P, Lechner K,
Valent P.
Serum tryptase measurements in patients with myelodysplastic syndromes.
Leuk Lymphoma.
2002;
43
1097-1105
- 46
Stankovic K, Sarrot-Reynauld F, Puget M, Massot C, Ninet J, Lorcerie B, Dupond J L,
Salles G, Durieu I, Vital Durand D, Rousset H.
Systemic mastocytosis: predictable factors of poor prognosis present at the onset
of the disease.
Eur J Intern Med.
2005;
16
387-390
- 47
Valent P, Akin C, Sperr W R, Mayerhofer M, Fodinger M, Fritsche-Polanz R, Sotlar K,
Escribano L, Arock M, Horny H P, Metcalfe D D.
Mastocytosis: pathology, genetics, and current options for therapy.
Leuk Lymphoma.
2005;
46
35-48
- 48
Williams A, Krishna T, Frew A.
Systemic mastocytosis.
Lancet.
2002;
360
1611
Priv.-Doz. Dr. Franziska Ruëff
Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität
München - Campus Innenstadt
Frauenlobstraße 9-11
80337 München
Phone: 0049/89/51606170
Fax: 0049/89/51606162
Email: Franziska.Rueff@med.uni-muenchen.de
